Companies / NUVB Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Ticker NUVB Exchange NYSE Sector Healthcare Industry Biotechnology Market cap $1.44B 52-week range $3.97 - $9.75 Valuation Share price $4.16 (close of Nov 6, 2026) P/E (TTM) -10.67x Price to book 6.32x Price to free cash flow -13.57x Enterprise value $1.59B Book value per share $0.66 Price performance Period Change 1 day -0.72% 5 days -12.61% 1 month -14.75% 3 months -31.91% 6 months -17.46% Year to date -53.57% 1 year -17.13% 3 years +215.15% 5 years -54.78% All time -57.11%
Short interest As of Oct 15, 2026 Short % of float 29.65% Shares short 63.22M Days to cover 9.66 Change since prior report +7.40% Source FINRA consolidated short interest Profitability and growth Return on equity -66.93% Return on invested capital -58.68% Return on assets -34.40% Return on capital employed -41.57% Gross margin 85.22% Net margin -325.31% EBITDA margin -335.96% Cash flow and balance sheet Free cash flow yield (TTM) -7.37% Current ratio 7.45x Net debt to EBITDA -1.36x Latest reported year Period end Dec 31, 2025 Fiscal year 2025 Revenue $62.90M Cost of revenue $9.30M Gross profit $53.60M EBITDA -$211.32M Net income -$204.63M Earnings per share $-0.60 Research and development $115.11M Interest expense $13.68M Shares outstanding 341.54M Income statement by year Period end Revenue Gross profit Net income EPS 2025-12-31 $62.90M $53.60M -$204.63M -$0.60 2024-12-31 $7.87M $795.00K -$567.94M -$2.11 2023-12-31 - - -$75.80M -$0.35 2022-12-31 - - -$104.20M -$0.48 2021-12-31 - - -$86.85M -$0.44 2020-12-31 - - -$41.66M -$0.43
Margins and returns by year Period end Gross margin Net margin Return on equity Return on capital 2025-12-31 85.22% -325.31% -66.93% -58.68% 2024-12-31 10.10% -7,213.76% -122.46% -125.37% 2023-12-31 - - -12.53% -16.39% 2022-12-31 - - -15.91% -18.16% 2021-12-31 - - -11.64% -12.46% 2020-12-31 - - -19.37% -19.87%
Cash and debt by year Period end Cash Debt 2025-12-31 $164.09M $47.21M 2024-12-31 $35.72M - 2023-12-31 $42.65M - 2022-12-31 $101.10M - 2021-12-31 $132.42M - 2020-12-31 $29.75M - 2019-12-31 $3.47M - 2018-12-31 $138.00K -
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$173.43M $35.89M 2024-12-31 -$130.41M $32.27M 2023-12-31 -$68.00M $19.51M 2022-12-31 -$96.11M $16.29M 2021-12-31 -$68.19M $9.27M 2020-12-31 -$36.53M $2.20M 2019-12-31 -$25.09M - 2018-12-31 -$616.00K -
Investor relations Past earnings dates Reported Fiscal period EPS estimate 2026-11-04 Sep 2026 -$0.11 2026-08-06 Jun 2026 -$0.15 2026-05-04 Mar 2026 $0.12 2026-03-02 Dec 2025 -$0.11 2025-11-03 Sep 2025 -$0.17 2025-08-07 Jun 2025 -$0.17 2025-05-07 Mar 2025 -$0.16 2025-03-06 Dec 2024 -$0.14
Filings and sources Company website nuvationbio.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades